{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:26:51Z","timestamp":1791563211869,"version":"4.3.4"},"reference-count":58,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Ono Pharmaceuticals","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,8,8]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hormone receptor (HR)-positive breast cancer is a disease for which no immune checkpoint inhibitors have shown promise as effective therapies. Cyclin-dependent kinase 4 and 6 (CDK4\/6) inhibitors synergistically increased the effectiveness of antiprogrammed cell death protein-1 (anti-PD-1)\/programmed death-ligand 1 (PD-L1) antibodies in preclinical studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This non-randomized, multicohort, phase II study evaluated the efficacy and safety of the anti-PD-1 antibody nivolumab 240 mg administered every 2 weeks in combination with the CDK4\/6 inhibitor abemaciclib 150 mg twice daily and either fulvestrant (FUL) or letrozole (LET) as a first-line or second-line treatment for HR-positive HER2-negative metastatic breast cancer. The primary end point was the objective response rate (ORR), and secondary end points were toxicity, progression-free survival, and overall survival. Blood, tissue, and fecal samples were collected at multiple points for correlative studies to evaluate immunity biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From June 2019 to early study termination due to safety concerns on July 2020, 17 patients were enrolled (FUL: n=12, LET: n=5). One patient with a prior treatment history in the FUL cohort was excluded. ORRs were 54.5% (6\/11) and 40.0% (2\/5) in the FUL and LET cohorts, respectively. Treatment-emergent (TE) adverse events (AEs) of grade \u22653 occurred in 11 (92%) and 5 (100%) patients in the FUL and LET cohorts, respectively. The most common grade \u22653 TEAEs were neutropenia (7 (58.3%) and 3 (60.0%) in the FUL and LET cohorts, respectively), followed by alanine aminotransferase elevation (5 (41.6%) and 4 (80.0%)). One treatment-related death from interstitial lung disease occurred in the LET cohort. Ten patients developed liver-related grade \u22653 AEs. Liver biopsy specimens from 3 patients showed hepatitis characterized by focal necrosis with predominant CD8+ lymphocyte infiltration. Marked elevation of tumor necrosis factor-related cytokines and interleukin-11, and a decrease in peripheral regulatory T cells (Tregs), were observed in patients with hepatotoxicity. These findings suggest that treatment-related toxicities were immune-related AEs likely caused by proinflammatory cytokine production and suppression of Treg proliferation due to the addition of abemaciclib to nivolumab therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although the combination of nivolumab and abemaciclib was active, it caused severe and prolonged immune-related AEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>JapicCTI-194782, jRCT2080224706, UMIN000036970.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2023-007126","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T01:00:30Z","timestamp":1694653230000},"page":"e007126","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":63,"title":["Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)"],"prefix":"10.1136","volume":"11","author":[{"given":"Jun","family":"Masuda","sequence":"first","affiliation":[{"name":"Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan"},{"name":"Department of Medical Oncology, Toranomon Hospital, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8396-9121","authenticated-orcid":false,"given":"Hitomi","family":"Sakai","sequence":"additional","affiliation":[{"name":"Advanced Cancer Translational Research Institute, Showa University, Shinagawa-ku, Tokyo, Japan"},{"name":"Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Tsurutani","sequence":"additional","affiliation":[{"name":"Advanced Cancer Translational Research Institute, Showa University, Shinagawa-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Toranomon Hospital, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan"},{"name":"Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Iwasa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan"},{"name":"Department of Breast Surgery, Hokkaido University Hospital, Sapporo, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Futamura","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Graduate School of Medicine, Gifu University, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hyogo Cancer Center, Akashi, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Aogi","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Aichi Cancer Center, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Hosonaga","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Mukohara","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center-Hospital East, Kashiwa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Department of Clinical Immuno-oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Shinagawa-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiyo K","family":"Imamura","sequence":"additional","affiliation":[{"name":"Advanced Cancer Translational Research Institute, Showa University, Shinagawa-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakiko","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Pathology, Showa University, Shinagawa-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiko","family":"Yamochi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Showa University, Shinagawa-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Kawabata","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Toranomon Hospital, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yasojima","sequence":"additional","affiliation":[{"name":"Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumoto","family":"Tomioka","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-5291","authenticated-orcid":false,"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan"},{"name":"Department of Medical Oncology, Toranomon Hospital, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"key":"2025100305413041000_11.9.e007126.1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2782"},{"key":"2025100305413041000_11.9.e007126.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01392"},{"key":"2025100305413041000_11.9.e007126.3","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in combination with Fulvestrant in women with HR+\/Her2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025100305413041000_11.9.e007126.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155"},{"key":"2025100305413041000_11.9.e007126.5","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of Abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"2025100305413041000_11.9.e007126.6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3452"},{"key":"2025100305413041000_11.9.e007126.7","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4537-5"},{"key":"2025100305413041000_11.9.e007126.8","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","article-title":"Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: A systematic review","volume":"2","author":"Stanton","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025100305413041000_11.9.e007126.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.11.010"},{"key":"2025100305413041000_11.9.e007126.10","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-020-01303-9","article-title":"Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with Clinicopathologic factors","volume":"22","author":"Guo","year":"2020","journal-title":"Breast Cancer Res"},{"key":"2025100305413041000_11.9.e007126.11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with Neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025100305413041000_11.9.e007126.12","doi-asserted-by":"publisher","DOI":"10.1038\/nature23465"},{"key":"2025100305413041000_11.9.e007126.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.02.053"},{"key":"2025100305413041000_11.9.e007126.14","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-022-00482-2","article-title":"Abemaciclib in combination with Pembrolizumab for HR+, Her2\u2212 metastatic breast cancer: phase 1B study","volume":"8","author":"Rugo","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"2025100305413041000_11.9.e007126.15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0915"},{"key":"2025100305413041000_11.9.e007126.16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1554"},{"key":"2025100305413041000_11.9.e007126.17","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1540"},{"key":"2025100305413041000_11.9.e007126.18","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","article-title":"Hepatotoxicity of immune Checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen","year":"2018","journal-title":"Mod Pathol"},{"key":"2025100305413041000_11.9.e007126.19","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in combination with Fulvestrant in women with HR+\/Her2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025100305413041000_11.9.e007126.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303"},{"key":"2025100305413041000_11.9.e007126.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709"},{"key":"2025100305413041000_11.9.e007126.22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","article-title":"Late-Onset and long-lasting immune-related adverse events from immune Checkpoint-inhibitors: an overlooked aspect in Immunotherapy","volume":"149","author":"Ghisoni","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025100305413041000_11.9.e007126.23","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0969"},{"key":"2025100305413041000_11.9.e007126.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102310"},{"key":"2025100305413041000_11.9.e007126.25","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan4236"},{"key":"2025100305413041000_11.9.e007126.26","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706"},{"key":"2025100305413041000_11.9.e007126.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01406-6"},{"key":"2025100305413041000_11.9.e007126.28","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","article-title":"Gut Microbiome correlates of response and toxicity following anti-Cd19 CAR T cell therapy","volume":"28","author":"Smith","year":"2022","journal-title":"Nat Med"},{"key":"2025100305413041000_11.9.e007126.29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx108"},{"key":"2025100305413041000_11.9.e007126.30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.3197"},{"key":"2025100305413041000_11.9.e007126.31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/CAD.0000000000000425","article-title":"Clinical effects of single nucleotide Polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with Sunitinib","volume":"28","author":"Numakura","year":"2017","journal-title":"Anticancer Drugs"},{"key":"2025100305413041000_11.9.e007126.32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2044"},{"key":"2025100305413041000_11.9.e007126.33","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16275"},{"key":"2025100305413041000_11.9.e007126.34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejca.2022.05.014","article-title":"Safety and efficacy of Nivolumab plus Bevacizumab, paclitaxel for Her2-negative metastatic breast cancer: primary results and biomarker data from a phase 2 trial (Wjog9917B)","volume":"171","author":"Ozaki","year":"2022","journal-title":"Eur J Cancer"},{"key":"2025100305413041000_11.9.e007126.35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30754-3"},{"key":"2025100305413041000_11.9.e007126.36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"2025100305413041000_11.9.e007126.37","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.59125","article-title":"Clinical implications of monitoring Nivolumab Immunokinetics in non-small cell lung cancer patients","volume":"3","author":"Osa","year":"2018","journal-title":"JCI Insight"},{"key":"2025100305413041000_11.9.e007126.38","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6391712","article-title":"Clinical features of liver injury induced by immune Checkpoint inhibitors in Japanese patients","volume":"2019","author":"Imoto","year":"2019","journal-title":"Can J Gastroenterol Hepatol"},{"key":"2025100305413041000_11.9.e007126.39","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005635","article-title":"Systematic comparison with autoimmune liver disease identifies specific histological features of immune Checkpoint inhibitor-related adverse events","volume":"10","author":"Coukos","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100305413041000_11.9.e007126.40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2821"},{"key":"2025100305413041000_11.9.e007126.41","article-title":"Abemaciclib in combination with Pembrolizumab for stage IV KRAS-Mutant or squamous NSCLC: A phase 1B study","volume":"2","author":"Pujol","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"2025100305413041000_11.9.e007126.42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2021.05.035","article-title":"Phase I\/II trial of Palbociclib, Pembrolizumab and Letrozole in patients with hormone receptor-positive metastatic breast cancer","volume":"154","author":"Yuan","year":"2021","journal-title":"Eur J Cancer"},{"issue":"15_suppl","key":"2025100305413041000_11.9.e007126.43","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1200\/JCO.2020.38.15_suppl.1051","article-title":"A phase IB study of Abemaciclib in combination with Pembrolizumab for patients with hormone receptor positive (HR+), human Epidermal growth factor receptor 2 negative (Her2-) locally advanced or metastatic breast cancer (MBC) (Nct02779751): interim results","volume":"38","author":"Rugo","year":"2020","journal-title":"JCO"},{"issue":"5_Supplement","key":"2025100305413041000_11.9.e007126.44","doi-asserted-by":"crossref","first-page":"GS3","DOI":"10.1158\/1538-7445.SABCS22-GS3-06","article-title":"Abstract Gs3-06: Gs3-06 Palbociclib after Cdk4\/6I and endocrine therapy (PACE): A randomized phase II study of Fulvestrant, Palbociclib, and Avelumab for endocrine pre-treated ER+\/Her2- metastatic breast cancer","volume":"83","author":"Mayer","year":"2023","journal-title":"Cancer Res"},{"key":"2025100305413041000_11.9.e007126.45","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/j.annonc.2022.03.108","article-title":"92Mo Neoadjuvant Nivolumab (NIVO) + Palbociclib (PALBO) + anastrozole (ANA) for estrogen receptor-positive (ER+)\/Human Epidermal growth factor receptor 2-negative (Her2-) primary breast cancer (BC): Checkmate 7A8","volume":"33","author":"Jerusalem","year":"2022","journal-title":"Annals of Oncology"},{"key":"2025100305413041000_11.9.e007126.46","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3930"},{"key":"2025100305413041000_11.9.e007126.47","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41575-021-00489-3","article-title":"Re-thinking the role of IL-11 in liver injury","volume":"18","author":"Ray","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025100305413041000_11.9.e007126.48","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1053\/j.gastro.2019.05.002","article-title":"Inhibiting interleukin 11 signaling reduces hepatocyte death and liver fibrosis, inflammation, and steatosis in Mouse models of Nonalcoholic Steatohepatitis","volume":"157","author":"Widjaja","year":"2019","journal-title":"Gastroenterology"},{"key":"2025100305413041000_11.9.e007126.49","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/hep.29215","article-title":"Pentraxin-3 modulates Lipopolysaccharide-induced inflammatory response and attenuates liver injury","volume":"66","author":"Perea","year":"2017","journal-title":"Hepatology"},{"key":"2025100305413041000_11.9.e007126.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"2025100305413041000_11.9.e007126.51","doi-asserted-by":"publisher","DOI":"10.1016\/S0192-0561(99)00037-5"},{"key":"2025100305413041000_11.9.e007126.52","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between Effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nat Immunol"},{"key":"2025100305413041000_11.9.e007126.53","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.45803-0"},{"key":"2025100305413041000_11.9.e007126.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2004.04.012"},{"key":"2025100305413041000_11.9.e007126.55","doi-asserted-by":"crossref","DOI":"10.3390\/foods11081153","article-title":"Relandscaping the gut Microbiota with a whole food: dose-response effects to common bean","volume":"11","author":"Lutsiv","year":"2022","journal-title":"Foods"},{"key":"2025100305413041000_11.9.e007126.56","doi-asserted-by":"publisher","DOI":"10.1038\/S41591-021-01655-5"},{"key":"2025100305413041000_11.9.e007126.57","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1126\/science.aaz7015","article-title":"Dietary fiber and Probiotics influence the gut Microbiome and Melanoma Immunotherapy response","volume":"374","author":"Spencer","year":"2021","journal-title":"Science"},{"key":"2025100305413041000_11.9.e007126.58","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e06438","article-title":"A novel Immuno-oncology algorithm measuring tumor Microenvironment to predict response to Immunotherapies","volume":"7","author":"Nielsen","year":"2021","journal-title":"Heliyon"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-007126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:41:43Z","timestamp":1759495303000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-007126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":58,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,13]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/jitc-2023-007126"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-007126","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}